Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression

HIV Medicine

Volumn 10, Issue 1, 2009, Pages 19-27

  Smith, C J ^a   Phillips, A N ^a   Dauer, B ^b   Johnson, M A ^c   Lampe, F C ^a   Youle, M S ^c   Tyrer, M ^c   Staszewski, S ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Three class failure; Viral rebound

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; REBOUND; RISK FACTOR; SEX DIFFERENCE; UNITED KINGDOM; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HIV INFECTIONS; HIV-1; HUMANS; LONDON; MALE; RECURRENCE; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 58049197830     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00650.x     Document Type: Article

References (25)

1. Gathe J, Cooper DA, Farthing C et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 Trial. Clin Infect Dis 2006; 43: 1337-1346.
2. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
3. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-2195.
4. Cahn P, Villacian J, Lazzarin A et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 Trial. Clin Infect Dis 2006; 43: 1347-1356.
5. Squires K, Pozniak A, Pierone G et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003; 139: 313-320.
6. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-718.
7. Lazzarin A, Queiroz-Telles F, Frank I et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. 16th International AIDS Conference. Toronto, ON, Canada, August 2006 [Abstract TUAB0104].
8. Grinsztejn B, Nguyen BY, Katlama C et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 159LB].
9. DeJesus E, Berger D, Markowitz M et al. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 160LB].
10. Benzie AA, Bansi LK, Sabin CA, Phillips AN for the UK Collaborative HIV Cohort. Increased duration of viral suppression is associated with lower failure rates regardless of previous treatment failures. AIDS 2007; 21: 1423-1430.
11. Phillips AN, Staszewski S, Lampe F et al. Human immunodeficiency virus rebound after suppression to <400copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186: 1086-1091.
12. Smith CJ, Phillips AN, Hill T et al. The rate of viral rebound after attainment of viral load below 50copies/mL according to specific antiretroviral drugs in use. J Infect Dis 2005; 192: 1387-1397.
13. Mocroft A, Ruiz L, Reiss P et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17: 1741-1751.
14. Anastos K, Schneider MF, Gange SJ et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39: 537-544.
15. Le Moing V, Chene G, Carrieri MP et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-29.
16. Sabin CA, Lampe F, Chaloner C et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic. HIV Med 2003; 4: 87-93.
17. Phillips AN, Miller V, Sabin C et al. Durability of HIV-1 viral load suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naïve individuals. AIDS 2001; 15: 2379-2384.
18. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
19. DeJesus E, McCarty D, Farthing CF et al. Once-daily vs. twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naïve adults with HIV infection: A randomized equivalence trial. Clin Infect Dis 2004; 39: 411-418.
20. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
21. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-1146.
22. Wood E, Montaner JS, Yip B et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1-infected injection drug users. CMAJ 2003; 169: 656-661.
23. Anastos K, Kalish LA, Hessol N et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: Results of the Women's Interagency HIV Study. AIDS 1999; 13: 1717-1726.
24. Glass TR, De Geest S, Hirschel B et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008; 13: 77-85.
25. Gardner EM, Sharma S, Peng G et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008; 22: 75-82.